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Abstract 
 
Background: Cancer/Testis Antigens (CTAs) are a subgroup of tumor-associated anti-
gens which are expressed normally in germ line cells and trophoblast, and aberrantly 
in a variety of malignancies. One of the most important CTAs is Developmental Pluri-
potency Associated-2(DPPA2) with unknown biological function. Considering the im-
portance of DPPA2 in developmental events and cancer, preparing a suitable plat-
form to analyze DPPA2 roles in the cells seems to be necessary.  
 
Methods: In this study, the coding sequence of DPPA2 gene was amplified and cloned 
into the retroviral expression vector to produce recombinant retrovirus. The viral par-
ticles were transducted to Esophageal Squamous Cell Carcinoma (ESCC) cell line (KYS 
E-30 cells) and the stable transducted cells were confirmed for ectopic expression of 
DPPA2 gene by real-time PCR.  
 
Results: According to the critical characteristics of retroviral expression system such as 
stable and long time expression of interested gene and also being safe due to deletion 
of retroviral pathogenic genes, this system was used to induce expression of DPPA2 
gene and a valuable platform to analyze its biological function was prepared. Trans-
duction results clearly showed efficient overexpression of the gene in target cells in 
protein level due to high level of GFP expression.  
 
Conclusion: Such strategies can be used to produce high levels of desired protein in 
target cells as a therapeutic target. The produced recombinant cells may present a 
valuable platform to analyze the effect of DPPA2 ectopic expression in target cells. 
Moreover, the introduction of its potential capacity into the mouse model to evaluate 
the tumorigenesis of these cancer cells in vivo leads to an understanding of the biolog-
ical importance of DPPA2 in tumorigenesis. In addition, our purified protein can be 
used in a mouse model to produce specific antibody developing a reliable detection 
of DPPA2 existence in any biological fluid through ELISA system.  
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Introduction 
 
Epigenetic modifications such as CpG DNA meth-
ylation are widely reprogrammed on a genome during 
embryogenesis. The embryonic cells of blastocyst, In-
ner Cell Mass (ICM) and the Primordial Stem Cells 
(PSCs) are categorized as totipotent stem cells which 
can differentiate into all different types of individual 
cells 1-3. Cancer cells share many similarities with germ 
line and embryonic cells, including deprogramming, 
invasive growth, proliferation, ability to self-renew and 
maintenance of the undifferentiated cell state. There- 
 
 
 
 
fore, it seems that embryonic active genes may be as-
sociated with these features of cancer cells. This hy-
pothesis existed based on the identification of several 
embryo-cancer transcripts which are expressed in hu-
man embryos and absent in normal differentiated so-
matic cells, but re-expressed in tumor cells 4,5. One of 
these transcripts is Developmental Pluripotency Asso-
ciated-2 (DPPA2) which subsequently entered into the 
gene databases as Embryo-Cancer Sequence A (ECSA) 
and is also known as Cancer Testis Antigen100 (CT100) 
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6,7. Cancer Testis Antigens (CTAs) are one of the most 
promising categories of Tumor-Associated Antigens 
(TAAs) in cancer-therapy, and over 140 members of 
CTAs, globally accounting for about 70 families, have 
been identified 8-14. The expression of CTAs normally 
restricted to germ cells in the testes, ovaries or tropho-
blasts 10,15,16. CTAs are divided into two groups, the X-
CTAs which are encoded by the X chromosome and 
represent about one-half of CT genes, and the non-X-
CTAs which are distributed throughout the genome and 
are mostly single-copy genes. It has been estimated 
that 10% of the genes on the X chromosome belonged 
to CTAs 10,17,18. The gene encoding DPPA2 in human 
maps to chromosome 3q13 over 8 exons and encodes a 
protein consisting of 297 amino acids. The primary 
structure of this protein contains a Spliceosome-As-
sociated Protein (SAP) motif and localizes to the nu-
cleus. This gene is expressed in different types of ma-
lignancies including lymphoma and lung, ovarian, liv-
er, and colon cancers 4,6.  
Few studies have focused on molecular epidemiolo-
gy of DPPA2 in cancer 19, and the biological function 
of this protein is unclear. Our aim in this study was to 
produce a stable transducted cell line which constitu-
tively express DPPA2 gene, helping to understand well 
about the DPPA2 biological role. A retroviral expres-
sion system was used in packaging cells to achieve 
high titers of recombinant virus particles. The results 
presented in this study demonstrate the feasibility of 
using this approach in expression of DPPA2 and to 
survey the function of this protein in any target cells. 
 
Materials and Methods 
 
Gene analysis 
The information of DPPA2 gene was obtained from 
NCBI database. The main characteristics of the gene 
such as gene and mRNA lengths, the coding sequence, 
and the number of probable pseudogenes were ana-
lyzed. 
 
Primer design 
After analyzing DPPA2 gene in different databases 
and a survey for its pseudogenes, cloning primer set1 
was designed using GeneRunner software version 3.05 
(Hastings Software Inc., Hastings, NY, USA) and check-
ed for probable hairpins, dimers, GC percentage and Tm. 
 
RNA extraction, cDNA synthesis 
Having searched protein atlas database (http://www. 
proteinatlas.org), it was shown that DPPA2 expressed 
cell lines. The selected cell lines were cultured, har-
vested, their total RNA were extracted using Trizol 
reagent (Invitrogen, Carlsbad, CA) and related cDNA 
was synthesized using oligo dT in first-strand cDNA 
synthesis kit (Fermentas, Vilnius, Lithuania) according 
to the manufacture's protocols.  
 
Real time PCR 
cDNAs were amplified on the Stratagene Mx-3000P 
real-time thermocycler (Stratagene, La Jolla, CA) with 
SYBR green mastermix (Invitrogen, Carlsbad, CA) con-
taining ROX as a reference dye and real time primer 
set presented in table 1. All experiments were per-
formed in duplicates. 
 
Amplification of DPPA2 coding sequence 
One microliter of cDNA (100 ng of total RNA) was 
used in PCR reaction with a final concentration of 1 
mmol/L magnesium chloride, 0.5 mmol/L deoxynucleo-
side triphosphate (Fermentas, Vilnius, Lithuania), 0.2 
units of Taq DNA polymerase (Fermentas, Vilnius, 
Lithuania), and 0/3 µl of each cloning primer set 1 in a 
final volume of 20 μl. The PCR condition was 95°C for 
5 min followed by 35 cycles of 95°C for 30 s, 55°C for 
30 s and 72°C for 45 s. 
Cycling was terminated with a final extension step 
of 7 min at 72°C. PCR products were visualized on a 
1% agarose/green viewer gel. 
 
TA cloning of amplified fragment 
RT-PCR product was cut off from agarose gel and 
purified using DNA extraction kit (Invitek GmbH, Ber-
lin, Germany), according to the manufacturer's recom-
mendation. The purified PCR product (5 to 10 ng) was 
cloned using TA cloning kit (Fermentas, Vilnius, Lith-
uania), according to the manual provided by the sup-
plier and followed by blue/white selection. 15 colonies 
of transformed Escherichia coli (E. coli) TOP10F' 
were picked, cultured, and subjected to colony PCR. 
Plasmid extraction was done on confirmed recombi-
nant colonies using plasmid extraction kit (GeNet Bio, 
Chungnam, Korea) and extracted plasmids were con-
firmed through colony PCR, double digestion with 
BamHI and XhoI restriction endonucleases and DNA 
sequencing. 
 
Characteristics of retroviral vector 
The retroviral vector backbone used in this study, 
pRUF-IRES-GFP, is a Murine Leukemia Virus-Based 
Vector which utilizes a MLV long terminal repeat 
(LTR). This vector was kindly provided by Dr. Paul 
Moretti (Hanson Institute, SA, Australia, http://www. 
hansoninstitute.sa.gov.au/). 
 
Sub cloning of amplified fragment in retroviral vector 
The pRUF plasmid was double digested with BamHI 
and XhoI and purified coding fragment of DPPA2 gene 
was ligated into the cloning site of pRUF which is 
cleaved with the same enzymes. After transformation, 
10 colonies of transformed E. coli TOP10F' were pick-
ed up, cultured, and subjected to plasmid extraction. 
The extracted plasmids were confirmed through colony 
PCR, double digestion with BamHI and XhoI enzymes 
and DNA sequencing.  
Table1. Real time primer set (1), Cloning primer set (2) 
 
Primer Primer sequences 
Forward primer 1 5'- AGAAATACAATCCAGGTCATCTACTTC -3' 
Reverse primer 1 5'- GCATATCTTGCCGTTGTTCAGG -3' 
Forward primer 2 5'- TTTTGGATCCCAGGGTGTTGCT -3' 
Reverse primer 2 5'-TTTTCTCGAGGTTGCTGCTACTTC-3' 
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Cell lines and culture 
GP293 and HEK293 (the Human Embryonic Kid-
ney cells 293T) as packaging cell lines and KYSE-30 
[Esophageal Squamous Cell Carcinoma (ESCC) cell 
line] as target cell line were cultured in DMEM and 
RPMI 1640, respectively, and both media were sup-
plemented with 10% FBS (Gibco, NY, USA), 1% (v/v) 
penicillin, streptomycin and incubated in an atmos-
phere of 5% CO2 at 37°C. 
 
Retroviral vector production 
High amount of pRUF-DPPA2, pVSV-G and pGP 
plasmids were produced in E. coli strain TOP10F' 
grown in LB medium supplemented with ampicillin 
(50 mg/ml). Plasmids were isolated and purified using 
Jetstar plasmid purification kit (Genomed, Bad Oeyn-
hausen, Germany). Quality and quantity of the plas-
mids were verified by gel electrophoresis and UV-spec-
trophotometry. For transfection in10 cm plate, 100 ng 
of each recombinant pRUF plasmid, plasmid encoding 
VSV-G protein and plasmid encoding Gag-Pol proteins 
were co-transfected into packaging cell lines separately 
using calcium phosphate method according to Tronolab 
protocol. Used solutions in this protocol included cal-
cium phosphate: 2.5 M solution in ddH₂O, sterile‐fil-
tered, 2 HEPES‐Buffered Saline (HBS): (for 500 ml) 
8 g NaCl, 0.38 g KCl, 0.1 g Na₂HPO₄, 5 g HEPES, 1 g 
glucose; pH=7.05, sterile‐filtered, MEM C supplement-
ed with 25 mM glucose. This protocol was adapted for 
10 cm dishes but it can be adapted to smaller or bigger 
plates. The timing has also been optimized for our 
needs but it supports some flexibility. This protocol 
was done in 5 days. Day 1 (Plating); the day before 
transfection, HEK293T cells were suspended in 90% 
DMEM/10% FCS (v/v) and seeded into cell‐culture 
dishes of 10 cm in diameter at a density of 2.5‐3 mil-
lion cells/plate. Day 2 (Transfection); transfection was 
carried out by the calcium phosphate method. For cal-
cium phosphate precipitation (1 ml/90 mm culture dish), 
20 µg of transfer vector (pRUF), 15 µg of packaging 
plasmid (pGP) and 6 µg of envelope plasmid (pVSV-
G) were put into a sterile reaction tube in final volume 
of approximately 150‐200 µl. Then 50 µl of 2.5 M cal-
cium chloride solution was added to this plasmid solu-
tion. The solution was brought to a volume of 500 µl 
with autoclaved ddH₂O. After transferring 500 µl of 
double‐concentrated HBS solution to another reaction 
tube, the calcium chloride solution was added to the 
HBS solution very slowly (dropwise), and the solution 
was mixed. Incubation at room temperature for 1 min 
was followed by dropwise addition of the precipitate to 
the cells under gentle shaking of the plate. The plate 
was then incubated at 37°C in a humidified atmosphere 
of 95% air and 5% CO₂. After 6‐8 hr of transfection, 
the calcium phosphate precipitate‐containing medium 
was removed and the cells were washed briefly with 5 
ml of 90% DMEM/10% FCS (v/v), then 6 ml of fresh 
MEMC supplemented with 25 mM glucose were added 
and the plate was incubated at 37°C in a humidified 
atmosphere of 95% air and 5% CO₂. Days 3, 4 and 5 
(Collection of virus); transfected cells were examined 
under an inverted fluorescence microscope (Olympus 
IX-70). A narrow band of GFP filter set (exciter D480/ 
20; emittor D520/20; Chroma, Brattleboro, VT) was 
used to detect the expression of the GFP in the cells. 
The virus‐containing supernatant was harvested into a 
sterile tube, centrifuged (3000 rpm, 5 min, RT), filtered 
through a 0.45 µm mesh filter and stored at 4°C. Then 
the supernatant was ultracentrifuged in the SW28 rotor 
(Beckman Instruments, Fullerton, CA, USA) at 73000 
g at 4°C for 2 hr to pellet the virus. After ultracentrifu-
gation, the supernatant was aspirated and the pelleted 
virus was resuspended in a small volume of cultivation 
medium and stored in aliquots at -80°C. Transfection 
of 293GP cells was carried out using the same protocol 
as HEK-293 cells but just with DPPA2-pRUF and 
pVSV-G plasmids. 
 
Transduction of target cells by enriched recombinant viral 
particles 
For transduction in a six-well plate, cells were seed-
ed prior to the day for transduction. One ml of virus 
supernatant was mixed with 1 ml of fresh RPMI/10% 
FBS containing 1% pen/strep and added to wells. The 
cell culture medium was changed 5-10 hr after trans-
duction. For detection of GFP expression, transduced 
cells were harvested 36-48 hr after transduction. Cells 
were examined under an inverted fluorescence micro-
scope (Olympus IX-70, Tokyo, Japan). A narrow band 
of GFP filter set (exciter D480/20; emittor D520/20; 
Chroma, Brattleboro, VT) was used to detect the ex-
pression of the GFP in the cells. 
 
Titration of retroviral vector by quantitative PCR (qPCR) 
KYSE-30 cells were transduced and the DNA was 
extracted using a genomic DNA extraction kit (Qiagen, 
Hilden, Germany). A fraction of this DNA was then 
analyzed for copy number of retroviral sequences using 
the Tronolab real-time PCR protocol. It measured the 
number of retroviral DNA copies integrated in the tar-
get cell genome. The ultimate test of the functionality 
of the vector was in cells supporting the activity of the 
promoter driving the transgene. Titration of retroviral 
particles was performed according to Tronolab proto-
col 20. Firstly, a mix (containing everything but the 
sample DNA) for the number of wells needed for the 
qPCR analysis, including all samples and standards in 
duplicates according to the following recipe (9 μl per 
well) was prepared: 10 μl SYBR green PCR Master 
Mix (Fermentas, Lithuania) and 1 μl forward/reverse 
mix primer (10 pM). Then, 2 μl of sample DNA to each 
of the appropriate wells was added. The amplification 
cycles used were: 1 cycle: 10 min 95C, then 40 cycles: 
15 s 95C, 30 s 60C and 20 s 72C. pAlb (available 
from Addgene, http://www.addgene.org) was a pRRL 
vector in which the target sequence of the albumin 
primers used for normalization has been cloned. This 
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plasmid allows performing a standard curve. Gag oligos 
were used for amplification of pRUF vector sequence 
and were specific for the 5′ end of the gag gene. This 
sequence was present in pRUF vector, as it was part of 
the extended packaging signal. Alb oligos were used to 
normalize the amount of genomic DNA and were spe-
cific for the human albumin gene (Table 2). Also cells 
were examined under an inverted fluorescence micro-
scope (Olympus IX-70). A narrow band of GFP filter 
set (exciter D480/20; emittor D520/20; Chroma, Brat-
tleboro, VT) was used to detect the expression of the 
GFP in the cells. 
 
Results 
 
Gene analysis and primer design  
DPPA2 gene was analyzed using NCBI database. 
The mRNA length of the gene is 1393 bp containing 9 
exons. The coding region on mRNA is from 248 to 
1144 bp which encodes 298aa. A pseudogene was 
found for DPPA2 coding sequence which is important 
in primer design. Alignment between the gene and its 
pseudogene was done using CLC work bench software 
version 5.6 (CLC bio, Aarhus, Denmark), and the per-
centage of homology was 92%. Since the length of 
pseudogene was 248 bp shorter than the DPPA2 
mRNA at 5’ end and due to the similar sequences of 
primary regions, forward primer designed 4 nucleo-
tides before the ATG initiation codon. Having analyzed 
the gene sequence, a cloning primer set presented in 
table 1 was designed. By substitution of 2 and 3 nucle-
otides, restriction sites were induced for BamHI (GGA- 
TCC) and XhoI (CTCGAG) in forward and reverse 
primers, respectively (Table 1). 
 
RNA extraction, cDNA synthesis 
Five cell lines including SKOV3, NCCIT, HEK293, 
Hela and HT that expressed DPPA2 gene were found 
using protein atlas site. Full length complementary 
DNA (cDNA) of DPPA2 coding sequence was synthe-
sized from the total RNA extracted from SKOV3, NC-
CIT, HEK293, Hela, HT cell lines. cDNA of SKOV3 
cell line was also synthesized by downstream primer.  
 
Real time PCR 
The expression level of DPPA2 in these cell lines 
was determined using real time PCR. The results re-
vealed that SKOV3 cell line has higher expression lev-
el than others. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
assay 
cDNA was amplified with gene specific primers by 
standardized PCR conditions. Resulting fragment of 
DPPA2 was 941 bp in size as expected when visual-
ized on agarose gel (Figure 1). 
 
TA cloning 
The amplified product was used for ligation in pTZ- 
57R/T cloning vector. The basis for ligation of any 
PCR product in this vector is the presence of over 
hanged adenines at both 3' and 5' ends of PCR product 
which binds complementary with thymine present at 
MCS of the linearized vector during ligation process. 
 
Transformation of E. coli with pTZ57R/T DPPA2 vector 
Competent cells of E. coli strain, TOP10F', were 
transformed with pTZ57R/TDPPA2 vector using cacl2 
method. Insertion of DPPA2 cDNA in multiple cloning 
sites of pTZ57R/T caused inactivation of Lac Z gene 
hence white colonies were produced on selection with 
X-Gal/IPTG containing media plates. Single transform-
ed white colonies were further used for colony PCR 
and plasmid extraction. The size of pTZ57R/T is 2886 
bp which was increased to 3827 bp after insertion of 
DPPA2 fragment and visualized by agarose gel elec-
trophoresis. 
 
Confirmation of DPPA2 through colony PCR, restriction 
digestion and sequencing 
After confirming through colony PCR, the recombi-
nant plasmid was extracted and digested with BamHI 
and XhoI resulting in release of about 941 bp fragment 
which was separated on 1% agarose gel (Figure 2). 
Finally, the sequence of PCR product in pTZ57R/ 
TDPPA2 vector was confirmed by sequencing. 
 
Sub cloning of DPPA2 gene in pRUF expression vector 
Competent cells of E. coli strain, TOP10F,' were 
transformed with pRUFDPPA2 vector.10 colonies of 
transformed E. coli were chosen and confirmed through 
colony PCR and double digested with BamHI and 
XhoI enzymes. The size of pRUF is 5950 bp which 
was increased to 6891 bp after insertion of DPPA2 
cDNA and visualized by agarose gel electrophoresis. 
Table 2. Primers for retrovectors' titration by qPCR 
 
Sequence 
detected Primer name Primer sequence 
Gag   
 
Gag forward GGAGCTAGAACGATTCGCAGTTA 
Gag reverse GGTGTAGCTGTCCCAGTATTTGTC 
Albumin   
 
Alb forward GCTGTCATCTCTTGTGGGCTGT 
Alb reverse ACTCATGGGAGCTGCTGGTTC 
 
Figure 1. PCR amplification of DPPA2. PCR product was 941 bp 
long as expected when visualized on agarose gel. 
Khaleghizadeh M, et al 
Avicenna Journal of Medical Biotechnology, Vol. 10, No. 2, April-June 2018    79 
After extraction of pRUFDPPA2 vector, this recombi-
nant plasmid was digested with BamHI and XhoI re-
sulting in release of about 941 bp fragment which was 
separated on 1% agarose gel to confirm the size (Fig-
ure 3). 
 
Retroviral vector production 
The pRUF plasmid is an expression vector contain-
ing GFP gene as a reporter gene, Internal Ribosome 
Entry Site (IRES), ampicillin resistant gene and re-
striction site for BamHI and XhoI enzymes (Figure 4). 
Recombinant pRUF-IRES-GFP was transiently co-
transfected along with the plasmids encoding VSV-G 
and Gag-Pol proteins into the HEK293 packaging cells. 
Cells were examined under an inverted fluorescence 
microscope (Olympus IX-70, Tokyo, Japan). A narrow 
band of GFP filter set (exciter D480/20; emittor 
D520/20; Chroma, Brattleboro, VT) was used to detect 
the expression of the GFP in the cells. The efficiency 
of transfection was about 10%. Recombinant pRUF 
with VSV-G plasmid were cotransfected into 293GP 
packaging cells which express gag and pol genes. The 
efficiency of transfection into 293GP was about 70% 
that was higher than HEK293 retroviral packaging cells 
(Figures 5A and 5B). These percentages were deter-
mined by measurement of GFP expression by flow-
cytometry analysis (data not shown). Viral superna-
tants were collected and used to infect KYSE-30 cells 
(Figure 5C). After transduction, viral titers were de-
termined by quantitative PCR (qPCR), and virus stocks 
containing 105TU/ml were obtained (Figure 6).  
 
Discussion 
 
Deprogramming or removal of the epigenetic infor-
mation returns the cell to the undifferentiated stem cell 
state 21-25. Embryonic genes which are active in plu-
ripotent embryonic stem cells may be associated with 
Figure 2. Recombinant pTZ57R/TDPPA2 digested with BamHI and 
XhoI. Digestion of  recombinant pTZ57R/TDPPA2 gives 2 bands that 
correspond to pTZ57R/T vector (2886 bp) and DPPA2 gene (941 bp). 
Figure 3. Sub cloning of DPPA2 gene in pRUF expression vector, A. Negative control plate; B. Sub cloning plate of DPPA2 gene; C. Colony PCR 
for confirming recombinant colonies, D. The size of pRUF vector was increased to 6891 bp after insertion of DPPA2 gene, E. Digestion of recombi-
nant pRUF-DPPA2 plasmid by BamHI and XhoI gives 2 bands that correspond to Pruf expression vector (5950 bp) and DPPA2 gene (941 bp). 
Figure 4. pRUF Retroviral Vector Map. This image was kindly pro-
vided by Paul Moretti, Hanson Institute, SA, Australia, http://www. 
hansoninstitute.sa.gov.au/ 
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similar properties presented in cancer cells involving 
deprogramming, unlimited proliferation, maintenance 
of the undifferentiated cell state, invasiveness as well 
as the ability to self-renew. Therefore, cancer cells may 
resemble stem cells through common functions and 
signals to initiate and progress deprogramming 4,5. 
Many cancers are associated with reactivation of germ 
cell and embryonic genes, e.g. the so-called Cancer/ 
Testis (CT) genes or CG genes 14,15,26,27. ECSA/DPPA2, 
also known as CT100, is a human embryonic antigen 
that is predominantly expressed in NSCLC (Non-small 
cell lung carcinoma) and also in other malignancies 
including melanoma, lymphoma, and in lung, liver and 
colorectal cancers 6,28. This may confirm involvement 
of embryonic stem cell properties in the cancer cells 
or/and cancer stem cell phenotype 28. Although the 
biological functions of this gene are not clear, ectopic 
expression of this transcription factor can help to un-
derstand the functional activity of this gene in the pro-
liferation and maintenance of stem cell activity of can-
cer cells. 
Up to now, several cell-targeting strategies have 
been developed to obtain the efficient mechanism for 
delivery of an interested gene to a particular target cell 
and operating its ectopic expression in vitro. Nucleic 
acids introduction into the target cells may be a medi-
cal purpose, and currently, different gene therapy stud-
ies are being developed 29,30. Since efficient expression 
of gene of interest in target cell is an essential step, 
integration of the gene into the host genome can lead to 
a long-term gene expression 31. Although several viral 
vectors have been developed for this reason, retroviral 
vectors may present promising qualities including large 
packaging size, long-term expression, capacity for cell 
targeting and scalable production 32,33.  
pRUF expression vector, as a retroviral vector, is a 
Murine Leukemia Virus-Based Vector. Retroviral vec-
tors are needed for packaging cells such as HEK293 or 
GP293. In this study, pRUF expression vector along 
with pVSV-G and pGP plasmids were cotransfected to 
packaging cells. The results presented here indicate 
that the efficiency of transfection to HEK293 is lower 
than GP293 cell line. GP293 is a packaging cell that 
stably expresses Gag-Pol protein, so efficiency of trans-
fection to GP293 is higher than HEK293. Several 
groups have recently reported the generation of high-
titer retroviral particles using transient transfection sys-
tems. pRUF contains an extended packaging signal, 
which is believed to be important for generating high-
titer viral preparations. To evaluate and monitor the 
gene transfer efficiency of these retroviral vectors, a 
GFP gene in this retroviral vector existed that exhibit-
ed fluorescence and was easily detected by fluores-
cence microscopy. pRUF is an IRES-GFP vector and 
GFP works as a reporter gene for monitoring and eval-
uation of viral transduction efficiency. By this retrovi-
ral vector system, there is no need to do western blot-
ting and IHC assays for confirming the expression of 
interested gene.  
In this research, DPPA2 gene was amplified and 
isolated by RT-PCR and the efficiency of cloning was 
increased by using TA cloning. The universal TA clon-
ing method relies on the supposition that all DNA 
fragments can be easily converted to double stranded 
DNA with over hanged adenines at both 3' ends, and 
thus the T-vector becomes a ready-for-ligation univer-
sal cloning vector.  
Our transduction results clearly showed efficient over 
expression of the gene in target cells in protein level 
due to high level of GFP expression. Such strategy can 
be used to produce high level of desired protein in tar-
Figure 5A-C. GFP expression in target cells 48 hr after transfection 
(×100) that were representative fluorescent photographs of HEK293T 
and GP293, respectively, under fluorescent microscope. 6C was rep-
resentative fluorescent photograph of target cell (KYSE-30) that was 
transducted by enriched recombinant viral particles. 
Figure 6. Titer estimation of retroviral vector using real-time RT-
PCR. Serial dilutions of pAlb vector were prepared. A) Amplification 
plot of samples with each dilution was represented in order from left 
to right on the graph. B) Standard curve generated from amplification 
plot is shown in A. Each sample was performed in duplicate and is 
represented as a dot. Overlapping dots are present in most of the 
dilutions illustrating the tight correlation within each dilution. Corre-
lation coefficient for Alb and Gag was 103.3 and 99.5%, respectively. 
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get cell as a therapeutic target. Interestingly, different 
cellular and molecular biology approaches (such as 
real-time PCR for gene expression pattern profiling, 
and proliferation and migration assay for analysis of 
cell behavior), can be developed to analyze the effect 
of protein ectopic expression in target cells. Further-
more, the produced cells with ectopic expression of 
target gene can be introduced to the mouse model to 
evaluate the tumorigenesis of these cancer cells in vivo, 
leading to an understanding of the biological import-
ance of DPPA2 in tumorigenesis. In addition, purified 
protein can be used in a mouse model to produce spe-
cific antibody, developing a reliable detection of DP-
PA2 existence in any biological fluid through ELISA 
system. 
 
Conclusion 
 
In summary, DPPA2 gene was successfully sub 
cloned and expressed in pRUF expression vector, and 
by producing a recombinant retrovirus, DPPA2 gene 
was transducted and expressed in KYSE-30 cell as a 
target cell. Since the function of DPPA2 is not clear, it 
can be used for understanding the biological function 
of this cancer testis antigen. Also, the recombinant 
DPPA2 protein that was produced by this recombinant 
retrovirus can be used in production of recombinant 
vaccines. 
 
Acknowledgement 
 
This study was a MSc thesis and supported by a 
grant from Mashhad University of Medical Sciences, 
Mashhad, Iran (# 910314). 
 
References 
 
1. Evans MJ, Kaufman MH. Establishment in culture of 
pluripotential cells from mouse embryos. Nature 1981; 
292(5819):154-156. 
 
2. Matsui Y, Zsebo K, Hogan BL. Derivation of pluripoten-
tial embryonic stem cells from murine primordial germ 
cells in culture. Cell 1992;70(5):841-847. 
 
3. Shi L, Wu J. Epigenetic regulation in mammalian pre-
implantation embryo development. Reprod Biol Endo-
crinol 2009;7:59. 
 
4. Monk M, Holding C. Human embryonic genes re-expres-
sed in cancer cells. Oncogene 2001;20(56):8085-8091. 
 
5. Ma Y, Zhang P, Wang F, Yang J, Yang Z, Qin H. The 
relationship between early embryo development and 
tumourigenesis. J Cell Mol Med 2010;14(12):2697-2701. 
 
6. John T, Caballero OL, Svobodová SJ, Kong A, Chua R, 
Browning J, et al. ECSA/DPPA2 is an embryo-cancer 
antigen that Is coexpressed with cancer-testis antigens in 
non-small cell lung cancer. Clinl Cancer Res 2008;14 
(11):3291-3298. 
 
7. Tung PY, Varlakhanova NV, Knoepfler PS. Identific-
ation of DPPA4 and DPPA2 as a novel family of pluri-
potency‐related oncogenes. Stem Cells 2013;31(11): 
2330-2342. 
 
8. van der Bruggen P, Traversari C, Chomez P, Lurquin C, 
De Plaen E, Van den Eynde B, et al. A gene encoding an 
antigen recognized by cytolytic T lymphocytes on a 
human melanoma. Science 1991;254(5038):1643-1647. 
 
9. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. 
Cancer/testis tumour-associated antigens: immunohisto-
chemical detection with monoclonal antibodies. Lancet 
Oncol 2003;4(2):104-109. 
 
10. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old 
LJ. Cancer/testis antigens, gametogenesis and cancer. 
Nat Rev Cancer 2005;5(8):615-625. 
 
11. Costa FF, Le Blanc K, Brodin B. Concise review: can-
cer/testis antigens, stem cells, and cancer. Stem Cells 
2007;25(3):707-711. 
 
12. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, 
Cohen T, Chua R, et al. Genome-wide analysis of cancer/ 
testis gene expression. Proc Natl Acad Sci USA 2008; 
105(51):20422-20427. 
 
13. Caballero OL, Chen YT. Cancer/testis (CT) antigens: po-
tential targets for immunotherapy. Cancer Sci 2009;100 
(11):2014-2021. 
 
14. Lim SH, Zhang Y, Zhang J. Cancer-testis antigens: the 
current status on antigen regulation and potential clinical 
use. Am J Blood Res 2012;2(1):29-35. 
 
15. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. 
Cancer/testis antigens: an expanding family of targets for 
cancer immunotherapy. Immunol Rev 2002;188:22-32. 
 
16. Scanlan MJ, Simpson A, Old LJ. The cancer/testis genes: 
review, standardization, and commentary. Cancer Immun 
2004;4:1. 
 
17. Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, 
Muzny D, et al. The DNA sequence of the human X 
chromosome. Nature 2005;434(7031):325-337. 
 
18. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli 
R, et al. The biology of cancer testis antigens: putative 
function, regulation and therapeutic potential. Mol Oncol 
2011;5(2):164-182. 
 
19. Raeisossadati R, Abbaszadegan MR, Moghbeli M, Ta-
vassoli A, Kihara AH, Forghanifard MM. Aberrant ex-
pression of DPPA2 and HIWI genes in colorectal cancer 
and their impacts on poor prognosis. Tumor Biol 2014; 
35(6):5299-5305. 
 
20. Barde I, Salmon P, Trono D. Production and titration of 
lentiviral vectors. Curr Protoc Neurosci 2010;Chapter 
4:Unit 4.21. 
 
21. Monk M, Boubelik M, Lehnert S. Temporal and regional 
changes in DNA methylation in the embryonic, extra-
embryonic and germ cell lineages during mouse embryo 
development. Development 1987;99(3):371-382. 
 
22. Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. 
Demethylation of the zygotic paternal genome. Nature 
2000;403(6769):501-502. 
 
23. Reik W, Dean W, Walter J. Epigenetic reprogramming in 
mammalian development. Science 2001;293(5532):1089-
1093. 
 
24. Smith AG. Mouse embryo stem cells: their identification, 
propagation and manipulation. Semin Cell Biol 1992;3 
(6):385-399. 
 
٨٢ 
Ectopic Expression of DPPA2 Gene 
Avicenna Journal of Medical Biotechnology, Vol. 10, No. 2, April-June 2018       82 
25. Loscalzo J, Handy DE. Epigenetic modifications: basic 
mechanisms and role in cardiovascular disease (2013 
Grover Conference series). Pulm Circ 2014;4(2):169-
174. 
 
26. Old LJ. Cancer/testis (CT) antigens - a new link between 
gametogenesis and cancer. Cancer Immun 2001;1:1. 
 
27. Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, 
Müntefering H, et al. Frequent nonrandom activation of 
germ-line genes in human cancer. Cancer Res 2004;64 
(17):5988-5993. 
 
28. Monk M, Hitchins M, Hawes S. Differential expression 
of the embryo/cancer gene ECSA (DPPA2), the cancer/ 
testis gene BORIS and the pluripotency structural gene 
OCT4, in human preimplantation development. Mol 
Hum Reprod 2008;14(6):347-355. 
 
29. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, 
Paton JF, Katovich MJ, et al. Efficient large-scale pro- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
duction and concentration of HIV-1-based lentiviral 
vectors for use in vivo. Physiol Genomics 2003;12(3): 
221-228. 
 
30. O’Keefe EP. Nucleic acid delivery: lentiviral and retro-
viral vectors. Labome com. 2013. 
 
31. Sinn P, Burnight ER, McCray PB Jr. Progress and pros-
pects: prospects of repeated pulmonary administration of 
viral vectors. Gene Ther 2009;16(9):1059-1065. 
 
32. Hu WS, Pathak VK. Design of retroviral vectors and 
helper cells for gene therapy. Pharmacol Rev 2000;52(4): 
493-512. 
 
33. Escors D, Kochan G, Stephenson H. Development of 
retroviral and lentiviral vectors. In: Escors D, Breckpot 
K, Arce F, Kochan G, Stephenson H, editors. Lentiviral 
vectors and gene therapy. New York: Springer; 2012. p. 
11-28. 
 
 
